WebDoctor Encyclopedia

Head & neck Lymphomas

Extranodal NK/T-cell lymphoma

Extranodal NK/T-cell lymphoma is a rare, aggressive, Epstein-Barr virus-linked lymphoma that usually starts in the nose or throat and destroys nearby tissue.

Medically reviewed Last reviewed October 21, 2026

What is extranodal NK/T-cell lymphoma?

Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive type of non-Hodgkin lymphoma. It develops from natural killer (NK) cells, or less often from cytotoxic T cells, which are white blood cells that normally destroy virus-infected cells.

“Extranodal” means that it usually starts outside the lymph nodes. In about 8 in 10 people, it begins in the nose, sinuses, throat or palate. It was formerly called “nasal type” NK/T-cell lymphoma, and very old texts call it “lethal midline granuloma”.

Almost every case is linked to the Epstein-Barr virus (EBV), the common virus that causes glandular fever. The lymphoma cells carry the virus.

ENKTL grows quickly and destroys tissue, so it needs fast treatment. When it is found early and treated with radiotherapy plus asparaginase-based chemotherapy, many people are cured. Immunotherapy with PD-1 inhibitors has also improved results for disease that comes back.

1. Key facts at a glance

Feature Details
How common Rare in Europe and North America (under 1% of lymphomas); much more common in East Asia and parts of Latin America
Typical age Adults, median age about 45-55
Sex Men are affected about 2-3 times more often than women
Main site Nasal cavity, nasopharynx, sinuses, palate and throat
Other sites Skin, gut, testis, soft tissue, lungs
Linked virus Epstein-Barr virus in nearly all cases
Main treatment Radiotherapy with asparaginase-based chemotherapy for early disease; asparaginase-based chemotherapy, often with a stem cell transplant, for advanced disease
Outlook About 60-80% long-term survival for early nasal disease; much lower for advanced disease

2. Causes and risk factors

Factor Notes
Epstein-Barr virus EBV is found in the lymphoma cells in almost all cases. Most people carry EBV harmlessly, so other factors must also be involved
Geography and ancestry Higher rates in China, Korea, Japan, Southeast Asia, Mexico, Central America and Peru, possibly due to genetic background (HLA types) and patterns of early EBV infection
Pesticides and solvents Linked in some studies
Gene changes in the tumour Acquired changes in genes such as STAT3, JAK3, DDX3X, TP53 and BCOR, and high levels of the immune checkpoint protein PD-L1

ENKTL is not inherited and not contagious, even though it is linked to a virus.

3. How does it look?

3.1 In the nose and face

Feature What it looks like
Nasal mass A soft, red or grey swelling inside the nose that bleeds easily
Ulcers and dead tissue Ulcers with black or yellow crusts and areas of necrosis (dead tissue), often with a foul smell
Tissue destruction The tumour can erode the nasal septum, the palate or the bones around the nose and eye. A hole in the roof of the mouth may form
Facial swelling Swelling of the cheek, nose or around the eye
Nose shape Collapse of the bridge of the nose in advanced cases

These changes are often mistaken at first for sinus infection, a fungal infection or granulomatosis with polyangiitis.

3.2 Outside the nose

Site Appearance
Skin Purple-red lumps, plaques or ulcers, often on the legs or trunk
Gut Ulcers in the bowel that can bleed or perforate
Testis A painless swollen testicle

3.3 Under the microscope

Feature Description
Growth pattern Lymphoma cells cluster around and invade blood vessel walls (angiocentric and angiodestructive), causing large areas of necrosis
Cells Medium-sized or mixed-size atypical lymphocytes
Markers CD56-positive, cytoplasmic CD3-epsilon positive, surface CD3 negative, and cytotoxic proteins (granzyme B, perforin, TIA-1)
EBV test EBV-encoded RNA (EBER) in the lymphoma cells; this is required for the diagnosis
Proliferation High Ki-67 index

Because of the necrosis, several deep biopsies are often needed to get enough living tumour tissue.

4. Symptoms

4.1 Nasal and throat disease

Symptom Details
Blocked nose Usually on one side at first, not improving with usual treatments
Nosebleeds Repeated or heavy
Discharge Bloody, crusting or foul-smelling discharge
Facial pain or swelling Around the nose, cheek or eye
Mouth problems Ulcers on the palate, loose teeth, difficulty swallowing
Eye symptoms Swelling, double vision or a bulging eye if the tumour reaches the eye socket
Voice and hearing Hoarseness, or blocked ears if the nasopharynx is involved

4.2 General (B) symptoms

Symptom Details
Fever Unexplained, often recurring
Night sweats Drenching
Weight loss More than 10% of body weight in 6 months

4.3 Other sites

Site Symptoms
Skin New lumps or ulcers that do not heal
Bowel Abdominal pain, diarrhoea, bleeding, or sudden severe pain from a perforation
Testis Swelling or heaviness

4.4 Haemophagocytic syndrome

A small number of people develop haemophagocytic lymphohistiocytosis (HLH), a dangerous over-activation of the immune system. It causes high fever, a large liver and spleen, low blood counts, very high ferritin and liver damage. It needs urgent hospital treatment.

5. Diagnosis

Test Purpose
Nasal endoscopy and deep biopsy Takes tissue from the edge of the lesion; often repeated if the first sample shows only necrosis
Immunohistochemistry and EBER Confirms the NK/T-cell type and the presence of EBV
PET-CT Shows how far the lymphoma has spread
MRI of the face and sinuses Shows local spread into bone, eye socket or skull base
Plasma EBV DNA Measures the amount of virus in blood; higher levels predict worse outcome and help track response
Bone marrow biopsy Checks for marrow involvement
Blood tests Full blood count, LDH, liver and kidney function, ferritin
Lumbar puncture In some high-risk cases, to check the spinal fluid

5.1 Staging and risk scores

Staging uses the Ann Arbor/Lugano system:

Stage Meaning
Stage I Lymphoma confined to one area, usually the nose
Stage II Spread to lymph nodes in the neck
Stages III-IV Widespread disease or spread to distant organs

The PINK score (Prognostic Index of Natural Killer lymphoma) predicts outcome using age over 60, stage III-IV, distant lymph node spread, and non-nasal primary site. Adding blood EBV DNA gives the PINK-E score.

6. Treatment

6.1 Why standard lymphoma chemotherapy does not work well

ENKTL cells often carry a pump protein (P-glycoprotein) that pushes drugs such as doxorubicin out of the cell. For this reason, the standard CHOP regimen works poorly. Modern treatment relies on L-asparaginase or pegaspargase, which starves the lymphoma cells of an amino acid they need.

6.2 Early-stage disease (stages I-II)

Treatment combines radiotherapy with non-anthracycline, asparaginase-based chemotherapy:

Component Details
Radiotherapy Usually 50-56 Gy to the nose and surrounding area, using precise techniques (IMRT)
Chemotherapy Given at the same time (concurrent) or before and after radiotherapy (sequential). Examples include P-GemOx, DDGP, VIPD and DeVIC
Results In a Japanese trial of concurrent radiotherapy with DeVIC chemotherapy, about 70% were alive at 2 years; later asparaginase regimens have given similar or better results

Radiotherapy alone may be used for very limited disease in people unable to have chemotherapy.

6.3 Advanced disease (stages III-IV)

Option Details
SMILE Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide. About 80% respond, but side effects, especially infections, are significant
P-GemOx, DDGP or AspaMetDex Asparaginase-based regimens that are often better tolerated. In a Chinese trial, DDGP gave better results than SMILE
Autologous stem cell transplant Often used to consolidate a complete remission
Radiotherapy To bulky or residual sites

6.4 Relapsed or refractory disease

Option Details
PD-1 inhibitors Pembrolizumab, nivolumab, sintilimab and others. Response rates of about 40-75% have been reported in people whose disease relapsed after asparaginase
PD-L1 inhibitors Sugemalimab is approved in China for relapsed ENKTL
Allogeneic stem cell transplant From a donor; may cure some people who respond to further treatment
Clinical trials Including targeted drugs and EBV-directed cell therapy

6.5 Supportive care

Need Help
Nasal care Saline rinses and crust removal
Mouth care Gentle mouthwashes, dental review before radiotherapy
Nutrition Dietitian support, especially during radiotherapy
Infection prevention Antibiotic and antiviral prophylaxis during intensive chemotherapy
Reconstructive surgery For palate holes or facial damage after cure

6.6 Possible side effects of treatment

Treatment Common side effects
Asparaginase or pegaspargase Allergic reactions, inflammation of the pancreas, liver changes, low fibrinogen and blood clots, high blood sugar
Chemotherapy (general) Low blood counts, infections, tiredness, nausea, hair loss
Radiotherapy to the nose Sore, dry nose and mouth, crusting, loss of taste, skin redness; later, dry mouth, dental problems and, rarely, eye or hormone changes
PD-1 inhibitors Immune-related inflammation of the skin, thyroid, bowel, liver or lungs, which usually responds to steroids
Stem cell transplant Serious infections; after a donor transplant, graft-versus-host disease

Your team will check blood tests regularly and adjust doses to keep treatment as safe as possible. Report fever, severe abdominal pain, leg swelling or breathlessness straight away.

7. Outlook (prognosis)

Situation Approximate outcome
Early-stage nasal disease, modern treatment About 60-80% alive at 5 years
Advanced-stage disease Roughly 30-40% alive at 5 years, depending on treatment and risk score
Relapsed disease Poor historically; PD-1 inhibitors and transplant have improved results for some

Factors linked to a worse outlook include advanced stage, high blood EBV DNA, high LDH, non-nasal primary site, older age and HLH. Having undetectable EBV DNA after treatment is a good sign.

8. Follow-up

What How often
Clinic visit and nasal endoscopy Every 3 months for 2 years, then less often
Plasma EBV DNA At each visit in the first years
Scans PET-CT or MRI at the end of treatment, then if symptoms or EBV DNA rise
Late effects checks Dry mouth, dental problems, eye and hormone changes after radiotherapy

9. Frequently asked questions

Question Answer
Can I catch it, or pass it on? No. EBV is very common and almost never causes lymphoma. The lymphoma itself cannot be passed on
Is it the same as nasal cancer? No. It is a lymphoma (a blood cancer) that happens to grow in the nose. It is treated differently from nasal carcinoma
Why did it take so long to diagnose? Early symptoms look like sinusitis, and the necrosis can make biopsies inconclusive
Will my face be changed? Some tissue loss can occur. Early treatment limits damage, and reconstructive surgery can help
Can it come back? Yes, most relapses happen in the first 2 years, which is why follow-up and EBV DNA tests are frequent then

Resources

  1. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  2. Campo, E. et al. (2022) ‘The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee’, Blood, 140(11), pp. 1229-1253.
  3. Haverkos, B.M. et al. (2016) ‘Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases’, Current Hematologic Malignancy Reports, 11(6), pp. 514-527.
  4. Au, W.Y. et al. (2009) ‘Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project’, Blood, 113(17), pp. 3931-3937.
  5. Kim, S.J. et al. (2016) ‘A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis’, The Lancet Oncology, 17(3), pp. 389-400.
  6. Suzuki, R. et al. (2011) ‘Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type’, Blood, 118(23), pp. 6018-6022.
  7. Yamaguchi, M. et al. (2009) ‘Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211’, Journal of Clinical Oncology, 27(33), pp. 5594-5600.
  8. Kwong, Y.L. et al. (2018) ‘Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma’, Annals of Oncology, 29(1), pp. 256-263.
  9. Yamaguchi, M. et al. (2011) ‘Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study’, Journal of Clinical Oncology, 29(33), pp. 4410-4416.
  10. Li, X. et al. (2016) ‘DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China’, Clinical Cancer Research, 22(21), pp. 5223-5228.
  11. Kwong, Y.L. et al. (2017) ‘PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase’, Blood, 129(17), pp. 2437-2442.
  12. Tao, R. et al. (2021) ‘Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)’, Signal Transduction and Targeted Therapy, 6(1), 365.
  13. National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.